Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 5/20 | 0.43 |
| ▸ | NOS1 | P29475 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | DHODH | Q02127 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13790658 | 0.91 | DHODH (0.55) | CA5AMKNK1MKNK2PARP1CYP3A4 | |
| SCHEMBL4730653 | 0.91 | FURIN (0.45) | CA5AMKNK1MKNK2PARP1NOS1 | |
| SCHEMBL813450 | 0.85 | PARP1 (0.53) | PARP1CYP3A4SMN1; SMN2TSHRDHODH | |
| SCHEMBL669554 | 0.85 | CA5A (0.67) | CA5ANOS1CYP3A4NOS3SMN1; SMN2 | |
| SCHEMBL24160674 | 0.85 | PARP10 (0.42) | CA5AMKNK1MKNK2PARP1NOS1 | |
| SCHEMBL28970077 | 0.85 | CA5A (0.40) | CA5AMKNK1MKNK2PARP1NOS1 | |
| SCHEMBL13307467 | 0.85 | CA5A (0.40) | CA5AMKNK1MKNK2PARP1NOS1 | |
| SCHEMBL25011455 | 0.85 | CA5A (0.40) | CA5AMKNK1MKNK2PARP1NOS1 | |
| SCHEMBL1086463 | 0.80 | PARP1 (0.63) | PARP1CYP3A4TSHRPOLBMAPT | |
| SCHEMBL22946249 | 0.80 | PARP10 (0.58) | CYP3A4SMN1; SMN2LMNATSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10784417-B2 | Wavelength conversion film | FUJIFILM CORPORATION (JP) | 2020-09-22 | — | — | US | disclosed |
| US-20190348578-A1 | WAVELENGTH CONVERSION FILM | FUJIFILM CORPORATION (JP) | 2019-11-14 | — | — | US | disclosed |
| WO-2017025298-A1 | CROSS-LINKED STAR-SHAPED SELF-ASSEMBLED POLYPEPTIDES AND ITS USE AS CARRIERS IN BIOMEDICAL APPLICATIONS | CENTRO DE INVESTIGACION PRINCIPE FELIPE (ES) | 2017-02-16 | — | — | WO | disclosed |
| US-7553831-B2 | Beta-secretase inhibitors; inhibiting cleavage of amyloid precursor protein (APP); hydroxy-functional disubstituted amines such as 6-(([[(2S,3S)-4-(3,5-difluorophenyl)-3-((3-[(dipropylamino)carbonyl]benzoyl)amino)-2-hydroxybutyl](ethyl)amino]carbonyl)amino)hexanoic acid | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7498436-B2 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY LLC (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080207677-A1 | Napthyridine Compounds As Rock Inhibitors | GPC BIOTECH AG (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080096942-A1 | Substituted Hydroxyethylamines | ELAN PHARMACEUTICALS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7312360-B2 | Substituted hydroxyethylamines | ELAN PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1833832-A1 | NAPTHYRIDINE COMPOUNDS AS ROCK INHIBITORS | GPC Biotech AG (DE) | 2007-09-19 | — | — | EP | disclosed |
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC | 2007-09-13 | — | — | US | disclosed |
| WO-2007060028-A1 | NAPTHYRIDINE COMPOUNDS AS ROCK INHIBITORS | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207677-A1 | Napthyridine Compounds As Rock Inhibitors | ROCK2, ROCK1, RHOT2 | CA5A 2058/4885MKNK1 1549/4885MKNK2 957/4885 |
| US-20080096942-A1 | Substituted Hydroxyethylamines | BACE1, BACE2, MME | CA5A 3619/4885MKNK1 4282/4885MKNK2 3982/4885 |
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, CHAT | CA5A 953/4885MKNK1 2763/4885MKNK2 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.